Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease (Q34706583)

4 August 2017

1 reference

title

Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease (English)

1 reference

4 August 2017

0 references

cardiovascular disease

1 reference

Jay P Garg

1

1 reference

PubMed ID

12083733

4 August 2017

George L Bakris

series ordinal

2

1 reference

4 August 2017

1 February 2002

1 reference

4 August 2017

1 reference

4 August 2017

7

1 reference

4 August 2017

1

1 reference

4 August 2017

35-43

1 reference

Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey

4 August 2017

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Microalbuminuria as predictor of increased mortality in elderly people

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Diabetic nephropathy. Future avenue

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Microalbuminuria and its relation to cardiovascular disease and risk factors. A population-based study of 1254 hypertensive individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: The Gubbio Population Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Albuminuria in normals and essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Microalbuminuria, blood pressure, metabolic control, and renal involvement: longitudinal studies in white non-insulin-dependent diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Effect of lipid reduction on the progression of renal disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Preservation of renal function: the spectrum of effects by calcium-channel blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Microalbuminuria: pathogenesis, prognosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Microalbuminuria in patients with NIDDM: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Microalbuminuria. Implications for micro- and macrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Endothelial dysfunction and pathogenesis of diabetic angiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Microalbuminuria as a marker of cardiovascular and renal disease in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Microalbuminuria in hypertension: is it up to measure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Hyperinsulinemic microalbuminuria. A new risk indicator for coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Microalbuminuria: a genetic link between diabetes and cardiovascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

U.K. Prospective Diabetes Study XV: Relationship of renin-angiotensin system gene polymorphisms with microalbuminuria in NIDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Microalbuminuria and associated cardiovascular risk factors in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Prevalence and clinical correlates of microalbuminuria in stage I hypertension. Results from the Hypertension and Ambulatory Recording Venetia Study (HARVEST Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Microalbuminuria and carotid artery intima-media thickness in nondiabetic and NIDDM subjects. The Insulin Resistance Atherosclerosis Study (IRAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X02VM412RA

10.1191/1358863X02VM412RA

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12083733